tirzepatide cvot trial Diabetes Distilled: “Twincretin” significantly SURPASSes comparator effects on glucose, weight and quality of life AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide

Cell Metab 17(6):819837 Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinsons disease: mechanisms of action

For a standard 5mg/mL semaglutide vial : 0.25mg = 5 units on an insulin syringe 0.5mg = 10 units 1.0mg = 20 units 1.7mg = 34 units 2.0mg = 40 units For a higher concentration vial , the unit count changes proportionally

Weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) versus CagriSema's 20.4% at 68 weeks (Phase 3 REDEFINE 1), though cross-trial comparisons are limited

We aim for the minimum effective dose, which is the dose that allows the operator to: Hit calorie goals consistently Maintain healthy fasting glucose, post-prandial (after meal) glucose, and fasting insulin levels Achieve the above without intolerable side effects like skin sensitivity or stomach discomfort Once the 16-week period is over, whether or not the desired physique is reached, the next phase begins